Circulating miRNAs as mediators in cell-to-cell communication

Christian Bär¹, Thomas Thum^{1,2} & David de Gonzalo-Calvo^{*,1,3,4,5}

¹Institute of Molecular & Translational Therapeutic Strategies (IMTTs), Hannover Medical School, 30625, Hannover, Germany

²National Heart & Lung Institute, Imperial College London, London, SW7 2AZ, UK

³Institute of Biomedical Research of Barcelona (IIBB) – Spanish National Research Council (CSIC), 08036, Barcelona, Spain

⁴CIBERCV, Institute of Health Carlos III, 28029, Madrid, Spain

⁵Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025, Barcelona, Spain

*Author for correspondence: Tel.: +34 93 556 5903; Fax: +34 93 556 5559; david.degonzalo@gmail.com

“circulating miRNAs may function as active hormone-like mediators. Understanding of the biology of circulating miRNAs is still at an early stage; therefore, further efforts are required to determine their precise role in intercellular communication.”

First draft submitted: 25 October 2018; Accepted for publication: 6 November 2018; Published online: 14 January 2019

Keywords: biological transport • cell-to-cell communication • endocrine genetic signal • miRNA

Since their discovery in the blood circulation in 2008 [1], miRNAs have emerged as the subclass of the noncoding RNA superfamily that has gained most attention in biomarker development. Due to their biochemical properties, the number of publications that have explored the clinical application of circulating miRNAs as diagnostic and prognostic indicators of cardiovascular disease has grown exponentially over the last decade [2]. Surprisingly, despite the enormous research and economic interest, the biology of these small noncoding RNAs in circulation is far from being completely understood.

In 2007, Valadi *et al.* [3] proposed for the first-time extracellular miRNAs as a novel paracrine mechanism for intercellular communication. Accordingly, extracellular miRNAs secreted by donor cells could be delivered into recipient cells where they function as endogenous miRNAs leading to altered gene expression. In just a few years thereafter, a growing body of data provided evidence supporting this hypothesis. *In vitro* studies suggest that the secretion of miRNAs is an active, controlled and specific process [4], that is presented in most, if not all, cell types. Different investigations have proposed miRNAs as intercellular communicators between cardiovascular cells, especially at the paracrine level. For instance, endothelial cell-derived apoptotic bodies generated during atherosclerosis contain miR-126 which acts as alarm signals to recipient vascular cells by inducing vascular protection [5]. In response to atheroprotective stimuli, endothelial cells secrete extracellular vesicles enriched in miR-143 and miR-145 both controlling target gene expression of co-cultured smooth muscle cells [6]. Bang *et al.* [7] identified cardiac fibroblast-derived miR-21-3p as exosome-specific paracrine signaling mediator of cardiomyocyte hypertrophy.

In addition to these findings, recently published *in vivo* studies also suggest a ‘hormone-like behavior’ of circulating miRNAs, especially in the context of cancer and metabolism. Focusing on the latter, Thomou *et al.* [8] demonstrated that circulating exosomal miRNAs participate in cell–cell crosstalk between adipose and liver tissue. Adipose-derived miRNAs enter the circulation and act as metabolic regulators in target tissues by altering mRNA expression and translation. Supporting the biological significance of circulating miRNAs as adipokines, Ying *et al.* [9] showed that adipose tissue macrophages secrete miRNA-containing exosomes which can function as endocrine signals in the regulation of the overall glucose homeostasis.

Concerning the cardiovascular system, the data published thus far is limited. Hence, a robust causal link between circulating miRNAs and cardiovascular physiology and pathology is still lacking. The association between nonrandom circulating miRNA signatures with a wide array of cardiovascular conditions observed in patient-based studies suggests that circulating miRNAs are actively and selectively released from cells in response to stress or injury [10]. Therefore, it is entirely conceivable that circulating miRNAs can function as signaling molecules in cardiovascular health and disease. This concept is supported by *in vivo* studies demonstrating that the systemic

delivery of miRNAs can induce biological responses in target cells and tissues [11]. Among the most convincing evidence that circulating miRNAs can act as hormone-like effectors in the cardiovascular system comes from Shan *et al.* [12], who reported circulating miR-223 as a novel endocrine genetic signal between blood cells, such as leukocytes and platelets, and vascular cells. Using both *in vitro* and *in vivo* approaches, the authors reported that blood cell-secreted miR-223 in serum enters into vascular smooth muscle cell, which do not express miR-223, and regulates their proliferation, migration and apoptosis. Under atherosclerotic conditions, the secretion of miR-223 is increased which protects against atherogenesis. In a similar study, it has been described that blood cell released miR-223 can also enter into endothelial cells and regulate the expression of its target genes [13]. Interestingly, this mechanism seems to be implicated in the vascular injury from Kawasaki disease.

Despite the promising findings, there are fundamental gaps that need to be addressed to elucidate the precise role of circulating miRNAs as intercellular mediators including their true biological significance in homeostasis and disease of cell types other than their origin. In this regard, different authors proposed that the concentration of miRNAs in plasma or serum is too low (from picomolar to femtomolar) to induce biological or pathological responses in their target cells and/or tissues [14]. Nonetheless, in this discussion the mechanisms of action of miRNAs should be taken into account. Several miRNAs may regulate the expression of the same gene. In contrast, different miRNAs (or just a single miRNA) may target multiple genes in the same molecular pathway. Estimations need to consider the concentrations of all delivered miRNAs that can regulate a given molecular pathway in the recipient cell. Assuming a 1:1 stoichiometry between miRNAs and their mRNA targets may be an oversimplification. Since the bioinformatics tools available to explore this hypothesis have strong limitations [15], currently, this analysis is virtually impossible. Additionally, a model for the selective uptake of circulating miRNA allowing sufficient intracellular accumulation to repress target mRNA expression should not be completely discarded. Importantly, the cellular machinery involved in the packaging of miRNAs in membrane vesicles or in protein/lipoprotein complexes and the mechanism of selection and secretion of circulating miRNAs have not been fully revealed. In fact, the cellular origin of many circulating miRNAs has been matter of debate. Platelets have been identified as a major source of circulating miRNAs [16]. However, different pieces of evidence suggest that the circulating miRNA profile is the reflection of the secretory pattern of multiple hematopoietic and nonhematopoietic cells [17]. Target tissue specificity of miRNA carriers, the delivery pathways of circulating miRNAs and how they mediate their biological effect on the recipient cell are also barely understood. Indeed, in addition to the expected presence of mature single-strand miRNAs in extracellular vesicles, precursor miRNAs and the machinery to process these precursor miRNAs into mature miRNAs has also been described in exosomes [18].

The technical limitations are a key aspect that deserves a careful discussion. Although different initiatives are working on the standardization of the methodology [19], there are considerable hurdles that should be overcome especially in the isolation of miRNA carriers and the quantification of circulating miRNA expression levels [20,21]. The use of artificial delivery systems and supraphysiological concentrations of exogenously applied miRNAs in *in vitro* and *in vivo* experiments should also be considered in the interpretation of the experimental data [14]. The cellular responses observed in these artificial conditions are not necessarily biologically relevant. Furthermore, the effect of miRNA carrier components on endogenous miRNA expression is a confounding factor that should be appropriately addressed (e.g., knockout models) in case the recipient cell is capable of expressing the miRNA of interest.

In conclusion, circulating miRNAs may function as active hormone-like mediators. Understanding of the biology of circulating miRNAs is still at an early stage; therefore, further efforts are required to determine their precise role in intercellular communication. The characterization of circulating miRNAs as endocrine genetic signals will provide exciting opportunities, not only for a better understanding of cardiovascular pathologies, but also for biomarker development and for the design of novel therapeutic approaches.

Financial & competing interests disclosure

This work was supported by Deutsche Forschungsgemeinschaft (Grant Number BA5631/2-1 to C Bär) and KFO311 (to T Thum). D de Gonzalo-Calvo was a recipient of Juan de la Cierva-Incorporación grant from the Ministerio de Economía y Competitividad (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403) is an Instituto de Salud Carlos III Project. T Thum has filed and licensed patents in the field of noncoding RNAs. T Thum is founder and holds shares of Cardior Pharmaceuticals GmbH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

1. Mitchell PS, Parkin RK, Kroh EM *et al.* Circulating microRNAs as stable blood-based markers for cancer detection. *Proc. Natl Acad. Sci. USA* 105(30), 10513–10518 (2008).
2. de Gonzalo-Calvo D, Iglesias-Gutierrez E, Llorente-Cortes V. Epigenetic biomarkers and cardiovascular disease: circulating microRNAs. *Rev. Esp. Cardiol. (Engl. Ed.)* 70(9), 763–769 (2017).
3. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* 9(6), 654–659 (2007).
4. de Gonzalo-Calvo D, Cenarro A, Garlaschelli K *et al.* Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. *J. Mol. Cell Cardiol.* 106, 55–67 (2017).
5. Zerneck A, Bidzhekov K, Noels H *et al.* Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci. Signal.* 2(100), ra81 (2009).
6. Hergenreider E, Heydt S, Treguer K *et al.* Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. *Nat. Cell Biol.* 14(3), 249–256 (2012).
7. Bang C, Batkai S, Dangwal S *et al.* Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J. Clin. Invest.* 124(5), 2136–2146 (2014).
8. Thomou T, Mori MA, Dreyfuss JM *et al.* Adipose-derived circulating miRNAs regulate gene expression in other tissues. *Nature* 542(7642), 450–455 (2017).
9. Ying W, Riopel M, Bandyopadhyay G *et al.* Adipose tissue macrophage-derived exosomal miRNAs can modulate *in vivo* and *in vitro* insulin sensitivity. *Cell* 171(2), 372–384 (2017).
10. de Gonzalo-Calvo D, Davalos A, Fernandez-Sanjurjo M *et al.* Circulating microRNAs as emerging cardiac biomarkers responsive to acute exercise. *Int. J. Cardiol.* 264, 130–136 (2018).
11. Jansen F, Stumpf T, Proebsting S *et al.* Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6. *J. Mol. Cell. Cardiol.* 104, 43–52 (2017).
12. Shan Z, Qin S, Li W *et al.* An endocrine genetic signal between blood cells and vascular smooth muscle cells: role of microRNA-223 in smooth muscle function and atherogenesis. *J. Am. Coll. Cardiol.* 65(23), 2526–2537 (2015).
13. Chu M, Wu R, Qin S *et al.* Bone marrow-derived microRNA-223 works as an endocrine genetic signal in vascular endothelial cells and participates in vascular injury from Kawasaki disease. *J. Am. Heart Assoc.* 6(2), e004878 (2017).
14. Witwer KW, Halushka MK. Toward the promise of microRNAs – enhancing reproducibility and rigor in microRNA research. *RNA Biol.* 13(11), 1103–1116 (2016).
15. Huntley RP, Kramarz B, Sawford T *et al.* Expanding the horizons of microRNA bioinformatics. *RNA* 24(8), 1005–1017 (2018).
16. Sunderland N, Skroblin P, Barwari T *et al.* MicroRNA Biomarkers and platelet reactivity: the clot thickens. *Circ. Res.* 120(2), 418–435 (2017).
17. Fehlmann T, Ludwig N, Backes C, Meese E, Keller A. Distribution of microRNA biomarker candidates in solid tissues and body fluids. *RNA Biol.* 13(11), 1084–1088 (2016).
18. Melo SA, Sugimoto H, O’Connell JT *et al.* Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell* 26(5), 707–721 (2014).
19. Lotvall J, Hill AF, Hochberg F *et al.* Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J. Extracell. Vesicles* 3, 26913 (2014).
20. de Ronde MWJ, Ruijter JM, Moerland PD, Creemers EE, Pinto-Sietsma SJ. Study design and qPCR data analysis guidelines for reliable circulating miRNA biomarker experiments: a review. *Clin. Chem.* 64(9), 1308–1318 (2018).
21. Sluijter JPG, Davidson SM, Boulanger CM *et al.* Extracellular vesicles in diagnostics and therapy of the ischaemic heart: position paper from the working group on Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovasc. Res.* 114(1), 19–34 (2018).